

FORM PTO-1390  
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

PF83PCTSEQ/dln

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/673288

INTERNATIONAL APPLICATION NO.  
PCT/FR99/00874INTERNATIONAL FILING DATE  
14 APR 1999 (14.04.1999)PRIORITY DATE CLAIMED  
14 APR 1998 (14.04.1998)TITLE OF INVENTION NOVEL CONSTRUCTS FOR CONTROLLED EXPRESSION OF RECOMBINANT PROTEINS  
IN PROKARYOTIC CELLSAPPLICANT(S) FOR DO/EO/US Laurent Chevalet, Alain Robert, Jean-Yves Bonnefoy &  
Thien Ngoc Nguyen

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 16 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:  
PCT 1B 301 & 304  
PTO 1449

ATTORNEY'S DOCKET NUMBER  
PF83PCTSEQ/dln

**CALCULATIONS**      PTO USE ONLY

\* \* \* \* \*

PF83PCTSEQ/dln

Applicants : Laurent Chevalet, Alain Robert, Jean-Yves  
Bonnefoy, and Thien Ngoc Nguyen  
Title : NOVEL CONSTRUCTS FOR CONTROLLED EXPRESSION  
OF RECOMBINANT PROTEINS IN PROKARYOTIC CELLS

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

As soon as the Serial No. and Filing Date have been accorded  
the above-identified application, kindly enter the following  
amendment:

IN THE CLAIMS:

Claim 1: Kindly amend as follows:

- 1 -

Method for producing a recombinant protein [of interest  
whose gene] wherein a gene encoding the protein is placed under  
the control of the P<sub>trp</sub> tryptophan operon promoter, [characterized  
in that it] wherein the method comprises the following steps:

- a) transforming a prokaryotic cell with a vector containing a  
nucleic acid sequence which is capable of inactivating the  
gene encoding a TnaA tryptophanase when said nucleic acid  
sequence is introduced into said host cell, and integrating  
said sequence into the DNA of said host cell; and before-  
hand, subsequently or simultaneously, introducing into said  
prokaryotic cell all[, ] or part[, ] of the sequence of a  
promoter which is followed, in the 3' position, by a

- 1 -

nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter or its transcription product;

- b) transforming said prokaryotic cell with a vector containing a gene encoding said recombinant protein [of interest];
- c) culturing said transformed cell in a culture medium which allows the expression of the recombinant protein; and
- d) recovering the recombinant protein from the culture medium or from said transformed cell.

Claim 2, line 1: Change "a" to --the--.

line 2: Delete "interest according to".

Claim 3, line 1: Change "a" to --the--.

line 2: Delete "interest according to either of" and change "Claim 1 and 2" to --Claim 1--.

Claim 4, line 2: Delete "interest according to one of" and change "Claims 1 to 3" to --Claim 1--.

Claim 5, line 2: Delete "interest according to one of" and change "Claims 1 to 4" to --Claim 1--.

line 3: Change "characterized in that" to --wherein--.

Claim 6, line 2: Delete "interest according to one of" and change "Claims 1 to 5" to --Claim 1--.

Claim 7, line 1: Change "according to" to --of--.

line 6: Insert a comma after "product".

Claim 8, line 1: Change "according to one of Claims 1 to 7" to --of Claim 1--.

line 2 Change "characterized in that" to --wherein--.

Claim 9, line 1: Change "according to one of Claims 1 to 8" to --of Claim 8--.

line 2: Change "characterized in that" to --wherein--.

Claim 10, line 4: Delete "of interest".

line 6: Change "characterized in that" to --wherein--.

Claim 11, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

Claim 12, line 1: Change "according to either of Claims" to --of Claim--.

line 2: Delete "and 11" and change "characterized in that" to --wherein--.

Claim 13, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

Claim 14, line 1: Change "according to either of Claims" to --of Claim--.

line 2: Delete "and 13" and change "characterized in that" to --wherein--.

Claim 15, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

Claim 16, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

Claim 17, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

Claim 18, line 1: Delete "according".

line 2: Change "to one of Claims 10 to 17" to -- of Claim 10--.

Claim 19, line 1: Change "according to" to --of-- and change

"characterized in" to --wherein--.

line 2: Delete "that" and delete "as defined in".

line 3: Delete "Example 1".

Claim 20, line 2: Delete "according to either" and change "Claims 18 and 19" to --Claim 18--.

Claim 21, line 1: Change "according to" to --of--.

line 2: Change "characterized in that" to --wherein--.

R E M A R K S

Editorial changes have been made in the claims to bring them more into line with standard U.S. practice.

Multiple dependencies and improper multiple dependencies have been eliminated.

Entry of the present amendment and early and favorable action on the merits of this application are respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN & SAGE

  
G. PATRICK SAGE, Attorney #37,710

Dated: October 12, 2000  
Customer No. 25,666  
715 The "H" Building  
310 East Michigan Ave.  
Kalamazoo, MI 49007  
616-382-0030

Enclosure: Return postal card receipt

4/PRTS

NOVEL CONSTRUCTS FOR CONTROLLED EXPRESSION OF  
RECOMBINANT PROTEINS IN PROKARYOTIC CELLS

The invention comprises a novel construct for  
5 expressing a gene encoding a recombinant protein of  
interest placed under the control of the P<sub>trp</sub>  
tryptophan operon promoter in a prokaryotic host cell,  
characterized in that the construct comprises a nucleic  
10 acid sequence which is capable of inactivating the gene  
encoding a TnaA tryptophanase when said nucleic acid  
sequence is introduced into said host cell, vectors  
containing said construct and the host cells  
transformed with said vectors. A subject of the  
invention is also the methods for producing said  
15 recombinant proteins using these novel constructs.

The present invention is generally used for  
producing recombinant polypeptides or proteins by so-  
called recombinant DNA methods. More particularly, the  
present invention relates to the production of  
20 recombinant polypeptides or proteins by transformed  
host cells which are bacterial in type, and in which  
expression is directed by or is under the control of  
the P<sub>trp</sub> tryptophan operon promoter/operator (Nichols &  
Yanofsky, 1983).

*Escherichia coli* (*E. coli*) is the most commonly  
25 used and best characterized organism for the purpose of  
production of recombinant proteins. Various expression  
systems are used in *E. coli* and, among them, the P<sub>trp</sub>  
tryptophan operon promoter is considered to be one of  
30 the strongest (Yansura & Bass, 1997).

However, not all recombinant genes are  
expressed with the same effectiveness by *E. coli*. It  
has been described and observed that the accumulation  
of a recombinant protein produced during the culturing  
35 of transformed host cells can rapidly lead to plasmid  
instability, a decrease in, or even an arrest of, cell  
growth, and a decrease in the overall yield of  
recombinant product. In this case, it is important to  
have available a system of controlled and regulated

expression which makes it possible to divide the production process into two phases; a first so-called cell growth phase in which the activity of the promoter is minimal, followed by a so-called induction or derepression phase which favors the expression and accumulation of the recombinant protein.

P<sub>trp</sub>, the tryptophan operon promoter of *E. coli*, is suitable for producing recombinant proteins because of its inducible nature. Repression at the level of the P<sub>trp</sub> operator is carried out by the product of the *trpR* regulatory gene, when this product, which is also named trp aporepressor, is bound to tryptophan (corepressor). Absence of tryptophan renders the TrpR protein incapable of binding to the operator, thus causing a derepression of the tryptophan operon. Diverse examples of expression of heterologous genes under the control of P<sub>trp</sub> show that the leaking of expression therefrom is too great to allow the production, under satisfactory conditions, of recombinant proteins, in particular those which are toxic for the cell (Yansura and Henner, 1990).

The TrpR regulatory protein is subjected to a self-regulation mechanism (Kelley & Yanofsky, 1982), and its concentration tends toward a mean value of 120 molecules per *E. coli* K-12 cell, in the presence of an excess of exogenous tryptophan (Gunsalus, Gunsalus Miguel & Gunsalus, 1986). This concentration, while it is sufficient to regulate correctly the activity of the single P<sub>trp</sub> chromosomal promoter, may prove to be limiting in the face of several tens of vectors containing the same promoter. With regard to tryptophan, it may also be a limiting factor even if it is provided in excess in the culture medium. In *E. coli*, there is, in fact, a tryptophanase activity which is encoded by the *tnaA* gene, and which is capable of degrading tryptophan to indole, thus diverting it from its regulatory function (Snell, 1975). In addition, tryptophanase can be induced by tryptophan, which makes any attempt to compensate this degradation



phenomenon with an increase in the supply of tryptophan pointless.

Various approaches directed towards obtaining the best possible control of leaking of expression have been envisaged and described. However, some have the drawback of only being applicable on a laboratory scale (Hasan & Szybalski, 1995; Suter-Crazzolara & Unsicker, 1995), or of decreasing the yield of recombinant product (Stark, 1987).

Consequently, there is, today, a great need to develop a system of controlled expression of recombinant proteins of interest which can be used on a large scale and which makes it possible, in particular, to control leaking of expression. This is precisely the subject of the present invention.

The invention relates to novel constructs based on the Ptrp expression system, which, when they are introduced into a prokaryotic host cell, preferably of bacterial type, make it possible to decrease the residual expression of recombinant genes at the start of culturing, these novel constructs providing improved control of the synthesis of recombinant proteins.

A subject of the present invention is a construct for expressing a gene encoding a recombinant protein of interest placed under the control of the Ptrp tryptophan operon promoter in a prokaryotic host cell, characterized in that the construct comprises a nucleic acid sequence which is capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell.

The expression "recombinant protein of interest" is intended to refer to all proteins, polypeptides or peptides which are obtained by genetic recombination, which can be used in fields such as human or animal health, cosmetology, human or animal nutrition, the agroindustry or the chemical industry. Among these proteins of interest mention may be made in particular, but without being limited thereto, of:

- a cytokine and in particular an interleukin, an interferon, a tissue necrosis factor and a growth factor, and in particular a hematopoietic growth factor (G-CSF, GM-CSF), a hormone such as human growth hormone  
5 or insulin, a neuropeptide,

- a factor or cofactor involved in clotting and in particular factor VIII, von Willebrand factor, antithrombin III, protein C, thrombin and hirudin,

- an enzyme and in particular trypsin, a  
10 ribonuclease and  $\beta$ -galactosidase,

- an enzyme inhibitor such as  $\alpha$ 1-anti-trypsin and viral protease inhibitors,

- a protein capable of inhibiting the initiation or progression of cancers, such as the expression products of tumor suppressor genes, for  
15 example the P53 gene,

- a protein capable of stimulating an immune response or an antibody, such as for example the proteins, or their active fragments, of the external  
20 membrane of a Gram-negative bacterium, in particular the OmpA proteins of Klebsiella or human respiratory syncytial virus protein G,

- a protein capable of inhibiting a viral infection or its development, for example the antigenic  
25 epitopes of the virus in question or modified variants of viral proteins which can compete with native viral proteins,

- a protein which can be contained in a cosmetic composition, such as substance P or a  
30 superoxide dismutase,

- a dietary protein,

- an enzyme capable of directing the synthesis of chemical or biological compounds, or capable of degrading certain toxic chemical compounds, or  
35 alternatively

- any protein which is toxic with respect to the microorganism which produces it, in particular if this microorganism is the bacterium *E. coli*, such as for example, but without being limited thereto, the

protease of the HIV-1 virus, the protein ECP (ECP for Eosinophil Cationic Protein) or the 2B and 3B proteins of poliovirus.

The expression "nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell" is intended to refer to a nucleic acid sequence capable of modifying said gene in such a way that this modification leads to the loss of tryptophanase activity of said host cell, the product of expression of said modified gene being incapable of degrading tryptophan to indole and thus diverting it from its regulatory function. Among said nucleic acid sequences capable of inactivating the gene coding for a TnaA tryptophanase when one of said nucleic acid sequences is introduced into said host cell, a nucleic acid sequence encoding an inactivated TnaA tryptophanase obtained by mutation, such as by substitution, insertion and/or deletion of at least one nucleotide of the nucleic acid sequence encoding an active TnaA tryptophanase, is preferred.

The invention comprises a construct according to the invention, characterized in that the prokaryotic host cell is a Gram-negative bacterium, preferably belonging to the *E. coli* species.

The invention also relates to a construct according to the invention, characterized in that it also comprises, upstream of said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell, all or part of the nucleic acid sequence of the *Ptna* tryptophanase operon promoter.

Preferably, the invention relates to a construct according to the invention, characterized in that said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell

comprises a mutated fragment of the coding sequence of said TnaA tryptophanase.

Preferably, the invention relates to a construct according to the invention, characterized in that said mutated fragment is obtained by inserting a stop codon at a position such that the sequence of the mutated fragment thus obtained encodes a protein fragment lacking tryptophanase activity.

Just as preferably, the invention relates to a construct according to the invention, characterized in that said mutated fragment is a mutated fragment of the coding sequence of the TnaA tryptophanase of said host cell.

With regard to the nucleic acid sequence encoding the TnaA tryptophanase of *E. coli*, and to its Ptna promoter, reference will be made in the present description to the sequence published by Deeley and Yanofsky (1981).

With regard to the nucleic acid sequences encoding the Ptrp tryptophan operon promoter/operator, reference will be made to the sequence published by Yanofsky et al. (1981).

The invention also relates to a construct according to the invention, characterized in that said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell comprises a nucleic acid sequence comprising all or part of the sequence of a promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter.

Preferably, the invention relates to a construct according to the invention, characterized in that said promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter, is all

or part of the *P<sub>trp</sub>* tryptophanase operon promoter of *E. coli*.

Equally preferably, the invention comprises a construct according to the invention, characterized in that said nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the *P<sub>trp</sub>* promoter, is the sequence encoding the *TrpR* tryptophan operon aporepressor of *E. coli* or one of its biologically active fragments such as the one described by Gunsalus and Yanofsky (1980).

The expression "a nucleic acid sequence comprising all or part of the sequence of a promoter" is intended to refer to a nucleic acid sequence comprising all the sequence of a promoter, or one of its biologically active fragments, which is capable of directing or of controlling the expression of a gene which is functionally linked to it.

In the present description, the expression "biologically active fragment of a promoter" will be intended to refer to any sequence of a fragment of said promoter, which fragment is capable of directing or of controlling the expression of the gene which is located downstream of said fragment, said gene being functionally linked to said fragment.

In the present description, the expression "biologically active fragment of the *TrpR* tryptophan operon aporepressor" will be intended to refer to any fragment of said aporepressor which has conserved its repressor activity.

The expression "nucleic acid sequence encoding a molecule which is ribonucleotide in nature, and which acts negatively on the *P<sub>trp</sub>* promoter", the preferred ribonucleotides are those chosen from the following sequences:

- a) 5' - AUUCGCGUCU ACGGCUUCAU CGUGUUGCGC - 3'
- b) 5' - AUUCGCGUCU ACGGCUUCAU CGUGUUGCGC AGCACAACGC  
GCCUGUCACC GGAUGUGUUU UCCGGUCUGA UGAGUCCGUG  
AGGACGAAAC AGG - 3'
- c) 5' - AUUCAGUACG AAAAUUGCUU UCAUAAUUCU AGAUACCCUU  
UUUACGUGAA CUU - 3'
- d) 5' - AUUCAGUACG AAAAUUGCUU UCAUAAUUCU AGAUACCCUU  
UUUACGUGAA CUUAGCACAA CGCGCCUGUC ACCGGAUGUG  
UUUCCGGUC UGAUGAGUCC GUGAGGACGA AACAGG - 3'
- e) 5' - AUUCGCGUCU ACGGCUUCAU CGUGUUGCGC AUUCAGUACG  
AAAAUUGCUU UCAUAAUUCU AGAUACCCUU UUUACGUGAA CUU - 3'
- f) 5' - AUUCGCGUCU ACGGCUUCAU CGUGUUGCGC AUUCAGUACG  
AAAAUUGCUU UCAUAAUUCU AGAUACCCUU UUUACGUGAA  
CUUAGCACAA CGCGCCUGUC ACCGGAUGUG UUUCCGGUC  
UGAUGAGUCC GUGAGGACGA AACAGG - 3'
- g) 5' - CUUCGCGUCC UGAUGAGUCC GUGAGGACGA AACGGCUUCC - 3'
- h) 5' - CUUCGCGUCC UGAUGAGUCC GUGAGGACGA AACGGCUUCC  
AGCACAACGC GCCUGUCACC GGAUGUGUUU UCCGGUCUGA  
UGAGUCCGUG AGGACGAAAC AGG - 3'.

Another aspect of the invention relates to a  
5 vector containing a construct according to the  
invention.

Preferably, the vector according to the  
invention is characterized in that it is the vector  
pMAK705[tnaAt] or the vector  
10 pMAK705[Ptna::trpR::3'tna].

The invention also relates to a prokaryotic  
host cell, preferably a bacterium of the *E. coli*  
species, transformed with a vector according to the  
invention.

15 In another aspect, a subject of the invention  
is a method for producing recombinant protein in a host  
cell using a construct according to the invention.

A subject of the invention is also a method for  
producing a recombinant protein of interest according  
20 to the invention, in which said construct is introduced  
into the DNA of the prokaryotic host cell.

Preference is given to a method for producing recombinant proteins according to the invention, in which said construct is introduced into the DNA of the prokaryotic host cell with a vector according to the invention, preferably according to the chromosomal  
5 integration method described in Example 1 or 2.

A subject of the invention is also a method for producing recombinant proteins according to the invention, in which said construct is introduced  
10 without any other DNA element which would allow a selective advantage to be associated therewith.

Preferably, the invention comprises a method for producing a recombinant protein of interest according to the invention, in which said construct is  
15 introduced at the tryptophanase operon locus of *E. coli*, preferably at the *tna* gene locus, and better still at the *tnaA* gene locus.

Preference is given to a method for producing recombinant proteins of interest according to the invention, characterized in that it comprises the  
20 following steps:

- a) transforming a prokaryotic cell with a vector according to the invention, and integrating said construct into the DNA of said host cell;
- 25 b) transforming said prokaryotic cell with a vector containing a gene encoding said recombinant protein of interest;
- c) culturing said transformed cell in a culture medium which allows the expression of the recombinant  
30 protein; and
- d) recovering the recombinant protein from the culture medium or from said transformed cell.

A subject of the invention is also a method for producing recombinant proteins of interest according to  
35 the invention, characterized in that said method also comprises, between step a) and b) of the above method, a resolution and a screening step.

The invention also relates to a method for producing recombinant proteins of interest according to

the invention, in which control of the expression of the recombinant proteins before induction of the Ptrp promoter is obtained by inducing said promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the  
5 Ptrp promoter according to the invention.

Finally, the invention also comprises a production method according to the invention, in which  
10 the induction of said promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter according to the invention, is obtained by any means  
15 enabling an inhibitory or activating effect to be exerted on said promoter.

Preferably, the invention comprises a production method according to the invention, in which the induction of said promoter which is followed, in  
20 the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter according to the invention, is obtained either:

- a) by choosing a suitable carbon source in the  
25 culture medium; or
- b) by adding tryptophan to the culture medium; or by a combination of a) and b).

The construct and vector systems, the prokaryotic host cells transformed with said vectors  
30 and the methods of the invention which are described above and which will be exemplified in the examples hereinbelow fall within the context of controlling the production of recombinant proteins in prokaryotic cells. They are suitable for the expression of  
35 homologous or heterologous genes placed downstream of the Ptrp promoter/operator. Two mutants are more particularly described below in order to illustrate the invention. They bear the names ICONE 100 and ICONE 200 (ICONE for Improved Cells for Over- and Non-leaky



Expression). The modifications introduced into the ICONE line have the following characteristics:

- 1) they are integrated into the host's chromosome,
- 5        2) since they are generated using a site-directed mutagenesis technique, they are targeted to a single site in the bacterial DNA, this site being completely known since it is the *tna* operon located at 83 min on the physical map of the *E. coli* K-12 genome.
- 10    In this respect, the consequences for the host from a physiological point of view are fully identified. In particular, the possibility that cryptic functions are reactivated following the chromosomal integration, as is suspected in the case of random mutagenesis, is
- 15    ruled out,
- 3) the technology used in these examples for the chromosomal integration (Hamilton et al. (1989)) excludes the possibility that other sequences are inserted into the bacterial DNA. In particular, the
- 20    mutants do not carry any genes for resistance to an antibiotic. Should they be used on an industrial scale, they offer the producer and the legislator the guarantee that they will have no selective advantage in the event of accidental dissemination in the
- 25    environment.

      According to one aspect of the invention, a first type of mutant or transformed cell named ICONE 100 is described, which carries a mutation in the *tnaA* gene, leading to a loss of tryptophanase activity.

30    The phenotype associated with this mutation is an absence of tryptophan degradation. This type of mutant, after transformation with a reporter vector and culturing on a medium which conventionally promotes tryptophanase activity, turns out to be superior to the

35    isolate from which it is derived in terms of control of repression by tryptophan.

      According to another aspect of the invention, a second type of mutant named ICONE 200 is described, which carries a cassette for expressing the *trpR* gene

under the control of the *Ptna* tryptophanase promoter, integrated at the *tnaA* gene locus. The use of the *tna* locus as a target for the integration leads, in the host bacterium, to a loss of tryptophanase activity, which causes, as described above, an inability to convert tryptophan to indole. Moreover, the presence of the *Ptna::trpR* cassette in the chromosome confers on this novel *trpR* gene the characteristics of *Ptna*, i.e. sensitivity to catabolic repression (Isaacs, Chao, Yanofsky, & Saier, 1994; Botsford & DeMoss, 1971) and inducibility by tryptophan (Stewart & Yanofsky, 1985). The latter property constitutes an innovation in which the plasmid *Ptrp* promoter is controlled, at the level of transcription, by a chromosomal promoter, *Ptna*, which is antagonistic to it. Surprisingly, after transformation with an expression vector and culturing in a fermenter, ICONE 200 turns out to be superior to the isolate from which it is derived in terms of control of repression by tryptophan.

The bacteria which have one of the characteristics mentioned above are useful for the controlled production of recombinant molecules thus, a subject of the present invention is also the use of said transformed bacteria in a method for producing recombinant proteins.

In the examples below, the advantage provided by the two mutants is clearly demonstrated using *Escherichia coli*  $\beta$ -galactosidase as the recombinant protein.

Another aspect of the invention lies in the characteristics of the mutations introduced. They are fully defined, controlled from a genetic and biochemical point of view, targeted to the *tna* locus of *E. coli*, and free of a selection marker.

The mutant or transformed microorganisms of the invention are constructed using prokaryotes, more precisely Gram-negative bacteria belonging to the *Escherichia coli* species. The properties of the tryptophanase operon promoter of *E. coli* (which can be

induced by tryptophan, sensitive to catabolic repression) were used to direct the transient synthesis of a mediator which acts negatively on Ptrp-directed expression. However, it is known that other bacterial species, in particular those which colonize the intestinal tract of animals, are capable of synthesizing a tryptophanase which can be induced by tryptophan (Snell. 1975). Consequently, other strains than *E. coli* are suitable for carrying out the methods described and for producing recombinant proteins therein.

The examples and figures which follow are intended to illustrate the invention without in any way limiting the scope thereof.

Legends of the figures:

**FIGURE 1:** Growth kinetics of the strains RV308, ICONE 100 and ICONE 200 x pVA- $\beta$ gal.

OD 580 nm corresponds to the measurement of the optical density measured by spectrophotometry.

**FIGURE 2:** Kinetics of  $\beta$ -gal activity of the strains RV308, ICONE 100 and ICONE 200 x pVA- $\beta$ gal.

The bacteria transformed with a vector containing the  $\beta$ -galactosidase gene under the control of the Ptrp promoter are cultured in a fermenter. The  $\beta$ -galactosidase activity is measured by incubating a cell extract in the presence of ONPG ( $\beta$ -galactosidase-specific substrate).

**FIGURE 3:** Comparison of the growth kinetics of the *E. coli* strains RV308 and ICONE 200 transformed with the vector pVA-polio2B.

**FIGURES 4A and 4B:** Immunoblot on the intracellular extracts of the RV308 and ICONE 200 cultures transformed with the vector pVA-polio2B.

Figure 4A: RV308 x pVA-polio2B

Figure 4B: ICONE 200 x pVA-polio2B

**FIGURE 5:** Analysis by SDS-PAGE of the polio-2B protein purified by nickel affinity chromatography.

**A :** Experiment No. 2: induction with 5  $\mu$ g/ml of IAA when the optical density is equal to 32.5;

**B** : Experiment No. 1: induction with 25 µg/ml of IAA when the optical density is equal to 32.5;

**C** : Experiment No. 4: induction with 5 µg/ml of IAA when the optical density is equal to 63.5;

5 **D** : Experiment No. 3: induction with 25 µg/ml of IAA when the optical density is equal to 62.5;

**MW** : molecular weight marker (kDa).

**FIGURE 6:** Growth kinetics of ICONE 200 x pVA-polio2B: influence of the induction time and of the inducer concentration.

■ Experiment No. 1: induction with 25 µg/ml of IAA when the optical density is equal to 32.5.

□ Experiment No. 2: induction with 5 µg/ml of IAA when the optical density is equal to 32.5.

15 ● Experiment No. 3: induction with 25 µg/ml of IAA when the optical density is equal to 62.5.

○ Experiment No. 4: induction with 5 µg/ml of IAA when the optical density is equal to 63.5.

The arrows indicate the moment of induction.

20 The invention is based on the stable introduction of mutations into the genome of the host strain. All the modifications given in the examples below are introduced at the *tna* locus of *E. coli*, consisting schematically of the following series:

- 25 A) P<sub>tna</sub> promoter,  
B) coding sequence of *tnaA* (tryptophanase) gene,  
C) intergenic region,  
D) coding sequence of the *tnaB* (tryptophan permease) gene,  
30 E) transcription terminator.

More specifically, the modifications relate to element (B). This is replaced to the benefit of an element (b), the characteristics of which in the diverse constructs are as follows:

**Table 1: Nature of the mutations carried by ICONE 100 and ICONE 200**

Mutant name	Nature of element (b)
ICONE 100	Coding sequence of <i>tnaA</i> interrupted at position +221 by a stop codon and an <i>XbaI</i> restriction site
ICONE 200	Coding sequence of the <i>trpR</i> gene encoding the <i>P<sub>trp</sub></i> aporepressor

5 Example 1: Construction of the mutant ICONE 100

A DNA fragment, marked *tnaAT*, is amplified by PCR. It stretches from position -275 to position +1054 with respect to the first nucleotide of the coding sequence of *tnaA*. This fragment, which overlaps *P<sub>tna</sub>* promoter and *tnaA*, is amplified by two-part PCR reaction. Part I stretches from position -275 to position +220. It is amplified with the aid of the oligonucleotides *Trp5* (sense) and *Trp2* (antisense), the sequence of which is:

15 *Trp5* : 5' - CGGGATCCGTGTGACCTCAAAATGGTT - 3'

BamHI

*Trp2* : 3' - CTACGCGCCGCTGCTTCGGATTAGATCTCG - 5'

(antisense)

stop *XbaI*

20

Part II is located in the coding sequence of *tnaA*, immediately 3' of part I. It stretches from position +221 to position +1054. It is amplified with the aid of the oligonucleotides *Trp3* and *Trp4*:

25

*Trp3* : 5' - CGTCTAGACAGCGGCAGTCGTAGCTAC - 3'

XbaI

*Trp4* : 3' - CCTTCTCTAACCGCAACAGTTCGAACG - 5'

(antisense)

HindIII

30

The PCR reactions are carried out using as a matrix *E. coli* K-12 colonies lysed in the Taq polymerase buffer (AmpliTaq Gold CETUS, USA).

The amplification products are precipitated  
5 with ethanol, and then digested with the suitable  
restriction enzymes (BamHI/XbaI for part I,  
XbaI/HindIII for part II). An analysis on agarose gel  
stained with ETB makes it possible to verify that the  
fragments have the expected size (Deeley & Yanofsky,  
10 1981). The tnaAT fragment is generated by ligating the  
two fragments I and II at the XbaI site. It differs  
from the natural sequence by the presence of a stop  
codon at position +221, followed by an XbaI restriction  
site. This tnaAT fragment is cloned into the vector  
15 pRIT28 (Hultman, Stahl, Hornes & Uhlen, 1989), at the  
BamHI/HindIII sites, and sequenced. The tnaAT fragment  
is subcloned into the vector pMAK705 (Hamilton, Aldea,  
Washburn, Babitzke & Kushner, 1989), giving  
pMAK705[tnaAT].

20 The method used to generate a genetic  
rearrangement in *E. coli* is the one described by  
Hamilton et al. (1989). It is based on the use of the  
suicide vector pMAK705, which carries a heat-sensitive  
origin of replication which is functional at 30°C but  
25 inactive beyond 42°C, and the chloramphenicol (CMP)  
resistance gene. *E. coli* RV308 (Maurer, Meyer &  
Ptashne, 1980) is transformed with 4 µg of vector  
pMAK705[tnaAT], and the transformation mixture is  
plated out on plates containing LB medium + 20 µg/ml  
30 CMP. After overnight incubation at 30°C, three clones  
are subcultured in LB liquid medium + 20 µg/ml CMP and  
incubated at 30°C with stirring until an OD at 580 nm  
close to 1 is reached. The suspensions are then plated  
out on LB medium + 20 µg/ml CMP and incubated at 44°C  
35 and at 30°C. The colonies which develop at 44°C (= co-  
integrants) are carrying a chromosomal integration of  
the vector, this integration being promoted by the  
existence of sequence homologies between the chromosome  
and the insert carried by the vector.

The so-called resolution phase consists in promoting the excision of the vector through a mechanism of recombination between repeated sequences present on the chromosome. Some clones isolated at 44°C are cultured in LB liquid medium + 20 µg/ml CMP at 30°C for three days, renewing the medium regularly. The suspensions are then diluted, plated out on LB agar medium + 20 µg/ml CMP, and incubated at 30°C until separate colonies appear. Several tens of colonies are subcultured in duplicate on LB agar medium + 20 µg/ml CMP at 30°C and 44°C. The colonies which do not develop at 44°C are selected and screened with a PCR reaction which indicates whether resolving the vector has conserved the stop codon and the XbaI site at the *tna* locus. The oligonucleotides used are Trp6 (sense) and Trp7 (antisense), which are homologous to the desired mutation and to a portion of the *tnaA* terminator, respectively:

Trp6 : 5' - CGACGAAGCCTAATCTAGA - 3'

stop XbaI

Trp7 : 3' - CCGATATTCCTACAATCGG - 5'

(antisense)

Out of eighteen screened clones, nine give an amplification fragment with the expected size indicating the presence of the stop codon followed by the XbaI site in the *tnaA* gene. The other nine clones do not give an amplification product, probably because the resolution step has restored on the chromosome the unmutated *tnaA* gene. Among the nine positive clones, four are sampled and subjected to a clearing out of the plasmid by successive subculturing in the absence of selection pressure. After culturing for a few days, clones are obtained which have again become sensitive to chloramphenicol.

The presence of *tnaA*-inactivating mutation is confirmed in two different ways: firstly, a PCR amplification with the aid of the oligonucleotides Trp5 and Trp4, followed by a digestion with XbaI shows that  
5 the restriction site, which is absent in *E. coli* RV308, is present in the *tnaA* gene of the mutants; next, by culturing the mutants in a tryptophan-rich medium, followed by the indole test (adding the Kovacs reagent to the culture medium), it is shown that the mutants  
10 have not generated indole, whereas the strain RV308 of origin produces indole under the same conditions. It is deduced therefrom that the mutation introduced leads to a loss of tryptophanase activity.

One clone is selected for the purpose of  
15 conservation in frozen form. It is named ICONE 100.

#### Example 2: Construction of the mutant ICONE 200

A DNA fragment is constructed in vitro by PCR amplification of three subunits.

20 The first subunit located in the *Ptna* promoter stretches from position -511 to position +3 with respect to the first nucleotide of the coding sequence of *tnaA*. It is amplified using the oligonucleotides TrpR1 (biotinylated in the 5' position) and TrpR2:

25 TrpR1: 5'-CTGGATCCCTGTCAGATGCGCTTCGC-3'

BamHI

TrpR2: 3'-CTTCCTAATACATTACCGGGTTG-5'

(antisense)

30

The second subunit corresponds to the coding sequence of the *trpR* gene of *E. coli*. It is amplified using the oligonucleotides TrpR3 and TrpR4 (biotinylated in the 5' position):

35



TrpR3 : 5' - GTAATGGCCCAACAATCACC - 3'

start

TrpR4 : 3' - CACAACGACTTTTCGCTAACTGACGTCAG - 5'

(antisense)

PstI

5

The third subunit corresponds to the sequence located immediately 3' of the coding sequence of *tnaA*. It contains the intergenic region of the *tna* operon and a portion of the *tnaB* gene encoding tryptophan permease. It is amplified using the oligonucleotides TrpR5 and TrpR6:

TrpR5 : 5' - CGCTGCAGTTAATACTACAGAGTGG - 3'

PstI

TrpR6 : 3' - CCAGCTAATGAGGTAAAGTTCGAAC - 5'

15

(antisense)

HindIII

The amplified fragments are purified according to the GeneClean method (Bio101, Jolla, CA, USA).

The subunits I and II are fused in the following way. In two separate tubes, each subunit is incubated with 30  $\mu$ l of streptavidin-labeled beads (Dynabeads, DYNAL, Norway). After 20 min at 37°C and 5 min at room temperature, the bound DNA is denatured with 50  $\mu$ l of 0.15 M NaOH. The single-stranded DNAs recovered in each supernatant are mixed in equal parts and subjected to a hybridization reaction and an extension reaction in the presence of Taq polymerase (AmpliTaq Gold, CETUS, USA) according to five PCR cycles. The reaction product is amplified in a PCR reaction with the aid of the oligonucleotides TrpR1 and TrpR4.

The GeneClean-purified amplification product is digested with BamHI and PstI. The fragment thus isolated is cloned into the vector pRIT28 to give pRIT28[Ptna::trpR], and then sequenced.

35

The subunit III is digested with the enzymes PstI and HindIII, then cloned into pRIT28 to give

pRIT28[3'tna], and then the sequence is verified by DNA sequencing (ABI 373A, Perkin Elmer, USA).

The vector pRIT28[Ptna::trpR] is digested with the enzymes PstI and HindIII, and then ligated in the presence of the subunit III, itself isolated from pRIT28[3'tna] by PstI/HindIII double digestion. The resulting vector is named pRIT28[Ptna::trpR::3'tna]. The insert is transferred into pMAK705 after double digestion with the enzymes BamHI and HindIII. The resulting plasmid is named pMAK705[Ptna::trpR::3'tna].

The integration of the Ptna::trpR::3'tna fusion at the tna locus of *E. coli* RV308 is carried out under conditions similar to those described in Example 1. Briefly, the strain is transformed with the vector pMAK705[Ptna::trpR::3'tna], and then subjected to the integration and resolution steps.

The screening of the colonies at the end of resolution uses conditions which are slightly different to those in Example 1. The tna locus is amplified by PCR using the oligonucleotides TrpR11 and TrpR7:

TrpR11: 5' - GGGCAGGTGAAC TGCTGGCG - 3'

TrpR7: 3' - GGTGCCGTTATAAGGGTCCGAC - 5'

(antisense)

TrpR11 hybridizes with the Ptna sequence upstream (5') of TrpR1, and TrpR7 hybridizes with the *tnaB* sequence downstream (3') of TrpR6. The amplification product has a different size depending on whether the gene placed downstream of Ptna is *tnaA* (situation encountered in RV308) or *trpR* (desired situation in the mutants). A colony which possesses *trpR* at the *tna* locus is conserved and named ICONE 200. An analysis of its chromosomal sequence shows that it possesses the *trpR* gene immediately downstream of the Ptna promoter. Culturing in the presence of tryptophan confirms the absence of indole formation, which is a logical consequence of the loss of the *tnaA* gene.

Example 3: Leaking of expression in the presence of succinate + tryptophan

This example describes the relative capacities  
5 of *E. coli* RV308, ICONE 100 and ICONE 200 to control  
the expression of a recombinant protein under the  
control of the *P<sub>trp</sub>* promoter. To this effect, we  
constructed an expression vector termed pVA- $\beta$ gal, in  
which the sequence encoding *E. coli*  $\beta$ -galactosidase is  
10 placed downstream of the *P<sub>trp</sub>* promoter. The vector of  
origin used for this construct is pVAABP308 (Murby,  
Samuelsson, Nguyen, et al., 1995).

Each of the three strains is transformed with  
the vector pVA- $\beta$ gal. The transformants obtained are  
15 cultured individually in a complete medium (30 g/l  
Tryptic Soy Broth (DIFCO), 5 g/l Yeast Extract (DIFCO))  
overnight at 37°C. An aliquot of these precultures is  
transferred into 60 ml of M9.YE.SUCC medium (1X M9 salt  
solution (DIFCO), 5 g/l Yeast Extract (DIFCO), 20 g/l  
20 sodium succinate). After an incubation time at 37°C  
which allows the exponential growth phase to be  
reached, a sample is removed from each culture. The  
growth is estimated via the optical density at 580 nm  
of the bacterial suspension. The level of  $\beta$ -  
25 galactosidase activity is measured in each cell pellet.  
For this, 1 ml of culture is centrifuged for 3 min at  
12 000 g. The cell pellet is taken up in 900  $\mu$ l of  
buffer (50 mM Tris-HCl, pH 7.5/1 mM EDTA/100 mM  
NaCl/400  $\mu$ g/ml lysozyme) and incubated for 15 min at  
30 37°C. 100  $\mu$ l of SDS (1% in 50 mM Tris-HCl, pH 7.5) are  
added, and the sample is placed at room temperature for  
5 min. The assay is carried out by mixing 30  $\mu$ l of  
sample, 204  $\mu$ l of buffer (50 mM Tris-HCl, pH 7.5/1 mM  
MgCl<sub>2</sub>) and 66  $\mu$ l of ONPG (4 mg/ml in 50 mM Tris-HCl,  
35 pH 7.5). The reaction mixture is incubated at 37°C. The  
reaction is stopped by adding 500  $\mu$ l of 1M Na<sub>2</sub>CO<sub>3</sub>. The  
OD at 420 nm, related to the incubation time, is  
proportional to the  $\beta$ -galactosidase activity present in  
the sample. Since it is known that *E. coli* RV308 has a

complete deletion of the lac operon (Maurer, Meyer & Ptashne, 1980), the  $\beta$ -galactosidase activity assayed is only due to the expression of the gene carried by the vector pVA- $\beta$ gal.

5 Table 2 summarizes the results obtained with each of the strains RV308, ICONE 100 and ICONE 200.

10 **Table 2: Growth of the strains RV308, ICONE 100 and ICONE 200 and leaking of expression (mean and standard error over three experiments)**

	OD 580 nm	$\beta$ -GAL (U/ml)
RV308	2.47 $\pm$ 0.01	0.93 $\pm$ 0.09
ICONE 100	3.69 $\pm$ 0.24	0.21 $\pm$ 0.03
ICONE 200	2.43 $\pm$ 0.03	0.02 $\pm$ 0.00

The results in Table 2 show that the mutants of the ICONE line develop at least as well as the strain  
15 RV308 from which they are derived. The mutations introduced thus have no negative effect on growth. Moreover, the  $\beta$ -galactosidase activity measured is different in the three strains. ICONE 100 has an intracellular activity which is approximately 4.5 times  
20 lower than that of RV308. Under "succinate as carbon source" conditions, in which the activity of Ptna promoter is at a maximum (Botsford & DeMoss, 1971), the deletion of the tryptophanase gene thus leads to a decrease in leaking of expression, probably by limiting  
25 the degradation of the intracellular tryptophan (corepressor). Under the same conditions, the degree of leaking of expression in ICONE 200 is further decreased by 10-fold with respect to ICONE 100. The activity of the plasmid Ptrp promoter is thus at a minimum in  
30 ICONE 200. Firstly, the loss of the tryptophanase activity gives the bacterium the possibility of controlling Ptrp better, as is demonstrated for ICONE 100. However, ICONE 200 has a second property which distinguishes it from ICONE 100 in genetic terms  
35 and gives it, at the experimental level, a further

advantage in terms of controlling expression. Thus, under conditions in which Ptna is active, ICONE 200 has the possibility of directing the overexpression of the TprR aporepressor, and, consequently, the leaking of expression measured at the level of the plasmid Ptrp promoter is decreased by a factor which is close to 50 with respect to the strain of origin RV308.

10 Example 4: Leaking of expression in the presence of  
glycerol + tryptophan

This example demonstrates the advantage provided by the mutant ICONE 200 in a fermentation culture medium and under fermentation conditions which are close to those which might be used industrially for producing recombinant proteins with the Ptrp system.

Each of the three strains RV308, ICONE 100 and ICONE 200 is transformed with the vector pVA- $\beta$ gal. The transformants obtained are cultured individually in 200 ml of complete medium (30 g/l Tryptic Soy Broth (DIFCO), 5 g/l Yeast Extract (DIFCO)) overnight at 37°C.

The cell suspension obtained is transferred sterily to a fermenter (model CF3000 from Chemap, capacity 3.5 l) containing 1.8 liters of the following medium (concentrations for 2 liters of final culture): 90 g/l glycerol, 5 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 6 g/l KH<sub>2</sub>PO<sub>4</sub>, 4 g/l K<sub>2</sub>HPO<sub>4</sub>, 9 g/l Na<sub>3</sub>-citrate.2H<sub>2</sub>O, 2 g/l MgSO<sub>4</sub>.7H<sub>2</sub>O, 1 g/l yeast extract, 30 mg/l CaCl<sub>2</sub>.2H<sub>2</sub>O, 8 mg/l ZnSO<sub>4</sub>.7H<sub>2</sub>O, 7 mg/l CoCl<sub>2</sub>.6H<sub>2</sub>O, 7 mg/l Na<sub>2</sub>MoO<sub>4</sub>.2H<sub>2</sub>O, 10 mg/l MnSO<sub>4</sub>.1H<sub>2</sub>O, 2 mg/l H<sub>3</sub>BO<sub>3</sub>, 8 mg/l CuSO<sub>4</sub>.5H<sub>2</sub>O, 54 mg/l FeCl<sub>3</sub>.6H<sub>2</sub>O, 0.06% antifoaming agent, 8 mg/l tetracycline and 200 mg/l tryptophan. The pH is regulated at 7.0 by adding aqueous ammonia. The dissolved oxygen content is maintained at 30% of saturation by automatically regulating the stirring speed and then the aeration flow rate, by measuring the dissolved O<sub>2</sub>. When the optical density of the culture reaches a value between 40 and 45, the induction is carried out by adding 25 mg/l of indole acrylic acid (SIGMA).

An analysis by kinetics of the optical density of the culture (OD at 580 nm of the suspension) and of the intracellular  $\beta$ -galactosidase activity (see Example 3) is carried out. Figures 1 and 2 illustrate, respectively, the growth kinetics and the kinetics of  $\beta$ -galactosidase activity of the three cultures.

The data given in Figure 1 confirm the observation in Example 3: the three strains have comparable growth kinetics. The mutants of the ICONE line have, from this point of view, conserved the growth potential of *E. coli* RV308, and they thus remain potential candidates for industrial use.

The data in Figure 2 show the impact of the mutations carried by the ICONE strains on the expression of the  $\beta$ -galactosidase in a fermenter. Clearly, on a glycerol-based medium, the presence or absence of the tryptophanase activity has no effect on the control of the expression, as attested thereto by the first part of the RV308 and ICONE 100 curves, even though it is observed that the exogenous tryptophan disappears more rapidly in the RV308 culture than in that of ICONE 100 (data not shown). On the other hand, the mutant ICONE 200 exhibits better capacities for controlling the expression at the start of culturing: the  $\beta$ -galactosidase activity remains low during the first 18 hours of culturing, and then begins to increase from  $t = 20$  h, the moment when the extracellular tryptophan concentration becomes zero (data not shown). The second part of the curve concerning ICONE 200 shows that the  $\beta$ -galactosidase activity increases evenly so as to reach a level at the end of culturing which is close to that obtained with RV308. In this respect, we demonstrate that the regulation system present in ICONE 200 provides a transient control of the plasmid *P*<sub>trp</sub> promoter. This control, exerted by the tryptophan and/or the carbon source, becomes ineffective in the second part of the culture and does not act against maximum expression of the recombinant protein.

The gene encoding the 2B protein is amplified from the vector pET3.2B (Lama et al., 1992) by a PCR reaction with the aid of the following oligonucleotides:

(sense) EcoRI

(antisense)      HindIII

The amplification product is then digested with the EcoRI and HindIII restriction enzymes, and then cloned into an expression vector which is derived from pBR322 and which carries the Ptrp tryptophan promoter. The resulting vector, named pVA-polio2B, carries a sequence encoding the 2B protein fused, at its C-terminal end, to a poly(His) tail, under the control of the Ptrp promoter.

The vector pVA-polio2B is introduced into the *E. coli* RV308 and ICONE 200 bacteria by transformation. A recombinant clone of each construct is then cultured under conditions which are similar to those described in Example 4.

The growth kinetics of the RV308 and ICONE 200 bacteria measured by the optical density at 580 nm are given in Figure 3. It appears clearly therein that RV308 exhibits a considerable growth delay: the mean  
5 generation time in the fermenter during the first 14 hours of culturing is 1 h 45 min, against only 1 h 17 min for ICONE 200. After culturing for 24 hours, the optical density for the strain RV308 is only equal to 13. Surprisingly, the strain ICONE 200 itself reaches  
10 an optical density equal to 37 after 17 h 30 min. of culturing, the time at which the induction is carried out by adding indole acrylic acid (IAA) at 25 µg/ml. The effect of the induction is immediate: the rate of oxygen consumption falls abruptly (data not shown) and  
15 growth stops.

Samples were taken at various culture times, and analyzed for their recombinant protein content. Samples of biomass centrifuged at 8000 g are taken up in a P1 buffer (25 mM Tris, 1.15 mM EDTA, 1 mg/ml  
20 lysozyme, pH 8) in a proportion of 5 ml per 1 g of biomass. The biomass is resuspended, incubated for 15 min. at room temperature, and then subjected to a sonication for 2 min. The lyzate is centrifuged again (10 000 g, 15 min., 4°C) so as to give a soluble  
25 fraction (supernatant) and an insoluble fraction (pellet taken up in 200 µl of P2 buffer: 25 mM Tris, 1 mM EDTA, pH 8). These samples are loaded onto polyacrylamide gel and subjected to an electrophoresis under denaturing conditions (SDS-PAGE). The gel is then  
30 transferred onto membrane according to the Western-blot technique in order to reveal the presence of the recombinant protein. The antibody used is a peroxidase-coupled anti-poly(His) monoclonal (Sigma). The revelation is performed by chemiluminescence with the  
35 ECL+ kit (Amersham). Figures 4A and 4B give the result of the immunoblots on the insoluble fractions derived from the RV308 and ICONE 200 cultures, respectively. Figure 4A shows that the recombinant protein is present in all the samples, i.e. from the start of culturing



until the fermentation time  $t = 24$  h, even though no induction with IAA has been carried out. Conversely, with ICONE 200, no recombinant protein is detected before induction (Figure 4B). It is only after  
5 induction with IAA that the 2B protein is detectable (in the insoluble fraction) and that the manifestation of its toxic nature is observed. Thus, these results demonstrate that the mutant ICONE 200 has a clear advantage with respect to the strain RV308 from which  
10 it is derived, and makes it possible to produce an effective control of expression in a fermenter.

#### Example 6: Production of a toxic protein

This example is directed toward demonstrating  
15 that a toxic protein can be expressed in a culture of ICONE 200 *E. coli* at high cell density and under culture conditions which are suitable for industrial extrapolation. For this purpose, the ICONE 200 *E. coli* strain transformed with the vector pVA-polio 2B is  
20 evaluated. The results obtained in Example 5 indicate that the induction conditions must be optimized if instantaneous growth arrest and then bacterial lysis, caused by the expression, are to be avoided. Thus, this example describes various assays intended to optimize  
25 the yield of recombinant protein per unit of fermented volume by adjusting the inducer concentration and the cell density at induction. The culture conditions used are those described in Example 4.

The experimental combinations tested are as  
30 follows:

- Experiment No. 1: induction with 25  $\mu\text{g/ml}$  of IAA when the optical density is between 30 and 35;
- Experiment No. 2: induction with 5  $\mu\text{g/ml}$  of IAA when the optical density is between 30 and 35;
- 35 ■ Experiment No. 3: induction with 25  $\mu\text{g/ml}$  of IAA when the optical density is between 60 and 65;
- Experiment No. 4: induction with 5  $\mu\text{g/ml}$  of IAA when the optical density is between 60 and 65.

For each experiment, samples of biomass are removed at various times after induction and analyzed according to the following protocol. Approximately 20 grams of biomass are taken up in 100 ml of 1X Start Buffer (prepared from the 8X concentrate: 1.42 g  $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ , 1.11 g  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 23.38 g  $\text{NaCl}$ , q.s. 100 ml, pH 7.4). The suspension is treated by sonication for  $3 \times 5$  min, and then centrifuged for 30 min at 20 000 g and  $4^\circ\text{C}$ . The pellet is taken up in 15 ml of Start Buffer + 6 M guanidine-HCl + 0.1% SB3-14 (N-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, Sigma), and then incubated in ice for 1 hour. The suspension is centrifuged for 1 hour at 30 000 g and  $4^\circ\text{C}$ . The supernatant is filtered through 0.45  $\mu$  with a view to purifying it by chelated-metal affinity chromatography. A column containing 1 ml of gel (HiTrap Chelating, Amersham Pharmacia Biotech) is loaded with 1 ml of 0.1 M  $\text{NiSO}_4$ , washed with 5 ml of water, and then equilibrated with 30 ml of Start Buffer + 6 M guanidine-HCl + 0.1% SB3-14. The sample is then loaded onto the column. A rinse with 60 ml of wash buffer (Start Buffer + 6 M guanidine-HCl + 0.1% SB3-14 + 20 mM imidazole) makes it possible to eliminate the majority of the proteins bound via nonspecific interactions. The recombinant polio-2B protein is eluted with  $10 \times 1$  ml of elution buffer (Start Buffer + 6 M guanidine-HCl + 0.1% SB3-14 + 300 mM imidazole). The fractions with the highest protein concentrations are pooled and then desalified on Sephadex G-25 gel (PD10 columns, Amersham Pharmacia Biotech). The quality and quantity of polio-2B protein thus obtained are estimated by electrophoresis under denaturing conditions (SDS-PAGE) and by assaying total proteins (BCA method, Pierce), respectively.

Figure 5 shows a Coomassie blue-stained SDS gel of the polio-2B proteins extracted and purified subsequent to experiments 1 to 4 described above. The size of the recombinant protein corresponds to the theoretical size (11 kDa) predicted from its coding

sequence. In addition, it corresponds to the size of the major protein observed on a Western blot after induction, in the ICONE 200 *E. coli* × pVApolio-2B lyzate (Figure 4B). It is thus probable that the  
5 proteins visible in Figure 5 correspond to the poliovirus 2B protein fused to a polyhistidine tail. Moreover, the quality of the proteins obtained is identical under all the induction conditions tested.

Table 3 below summarizes the results obtained  
10 by combining various factors such as optical density at induction, inducer concentration and culture time after induction.

**Table 3: Influence of the optical density at induction,  
15 of the inducer concentration and of the time after induction on the yield of expression of a toxic protein (example of polio-2B)**

Experiment No.	Optical density (580 nm) of the culture at the moment of induction	Inducer concentration (mg/l IAA)	Time after induction (HH:MM)	Quantity of protein extracted and purified (mg per liter of medium)
1	32.5	25	00:45	3
			01:45	2
2	32.5	5	00:45	6
			01:45	6
3	62.5	25	00:45	5.5
			02:45	7.5
4	63.5	5	00:45	6
			02:50	9

20 In comparing the groups of experiments (1-2) and (3-4), it is observed that the later the induction is carried out, the higher the yield of expression. This confirms the advantage of growing the biomass as much as possible before triggering the induction. In  
25 the case of experiments (3-4), approximately 70% of the

carbon substrate is consumed at the moment at which the expression of the polio-2B protein is triggered. With a strain such as ICONE 200, the cell growth phase and the expression phase are totally separated, which makes it possible to optimize the yield of recombinant protein, even when this protein is toxic.

In parallel with the induction time, the inducer concentration is also an influencing parameter. The best result of expression obtained in this example corresponds to experiment No. 4, in which the inducer concentration related to the number of cells is the lowest (5 mg/l of IAA for a culture with an optical density equal to 63.5). It is also in this experiment that the toxic effect of the expression of polio-2B is the least noticeable, since the culture continues to develop after induction, whereas growth is completely stopped in all the other experiments (see Figure 6). It is thus particularly important to adjust the conditions for induction of a toxic protein in such a way as to find the optimum between an inducer concentration which is too low to give rise to a significant expression and a concentration which is too high, provoking the immediate arrest of the bacterial metabolism. In comparing the results of experiments No. 4 and No. 1, it is observed that an induction which is later (OD = 63.5 against 32.5) and less strong (IAA concentration equal to 5 mg/l against 25 mg/l) makes it possible to multiply by 3- to 4-fold the quantity of recombinant protein obtained per unit of fermented volume.

The ICONE 200 *E. coli* strain, obtained by genetic modification according to the invention of a strain of industrial value, makes it possible to strictly control the expression of any gene placed in a plasmid vector downstream of the P<sub>trp</sub> tryptophan promoter. This control is transient since it is mediated by the exogenous tryptophan provided in the culture. The P<sub>trp</sub> induction potential in ICONE 200 is conserved, and remains possible to modulate via the IAA

concentration. Due to these properties, ICONE 200 allows the controlled expression of recombinant proteins under culture conditions which can be extrapolated to large scale.

## Bibliography

- Aldabe, R., Barco, A. & Carrasco, L., (1996). The Journal of Biological Chemistry 271, 23134-23137.
- 5 Botsford, J.L. & DeMoss, R.D. (1971). Catabolite repression of tryptophanase in *Escherichia coli*. Journal of Bacteriology, 105, 303-312.
- Deeley, M.C. & Yanofsky, C. (1981). Nucleotide sequence of the structural gene for tryptophanase of *Escherichia coli* K-12. Journal of Bacteriology, 147, 787-796.
- 10 Gunsalus, R.P., Yanofsky, C. (1980). Nucleotide sequence and expression of *E. coli* *trpR*, the structural gene for the *trp* aporepressor. Proceeding of the National Academy of Sciences, USA, 77, 12, 7117-7121.
- 15 Gunsalus, R.P., Gunsalus Miguel, A. & Gunsalus, G.L. (1986). Intracellular *Trp* repressor levels in *Escherichia coli*. Journal of Bacteriology, 167, 272-278.
- Hamilton, C.M., Aldea, M., Washburn, B.K., Babitzke, P. & Kushner, S.R. (1989). New method for generating deletions and gene replacements in *Escherichia coli*. Journal of Bacteriology, 171, 4617-4622.
- 20 Hasan, N. & Szybalski, W. (1995). Construction of *lacI*<sub>ts</sub> and *lacI*<sub>qts</sub> expression plasmids and evaluation of the thermosensitive *lac* repressor. Gene, 163, 35-40.
- 25 Hultman, T., Stahl, S., Hornes, E. & Uhlen, M. (1989). Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Research, 17, 4937-4946.
- Issacs, H., Chao, D., Yanofsky, C. & Saier, M.H. (1994). Mechanism of catabolite repression of tryptophanase synthesis in *Escherichia coli*. Microbiology, 140, 2125-2134.
- 30 Kelley, R.L. & Yanofsky, C. (1982). *trp* aporepressor production is controlled by autogenous regulation and inefficient translation. Proceedings of the National Academy of Sciences, USA, 79, 3120-3124.
- 35 Lama, J. & Carrasco, L. (1992). The Journal of Biological Chemistry 267, 15932-15937.

- Maurer, R., Meyer, B.J. & Ptashne, M. (1980). Gene regulation at the right operator (OR) of bacteriophage lambda. I. OR3 and autogenous negative control by repressor. *Journal of Molecular Biology*, 139, 147-161.
- 5 Murby, M., Samuelsson, E., Nguyen, T.N., Mignard, L., Power, U., Binz, H., Uhlen, M. & Stahl, S. (1995). Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. *European Journal of Biochemistry*, 230, 38-44.
- 10 Nichols, B.P. & Yanofsky, C. (1983). Plasmids containing the trp promoters of *Escherichia coli* and *Serratia marcescens* and their use in expressing cloned genes. *Methods of Enzymology*, 101, 155-164.
- 15 Snell, E.E. (1975). Tryptophanase: structure, catalytic activities, and mechanism of action. *Advances in Enzymology and Related Areas of Molecular Biology*, 42, 287-333.
- Stark, M.J.R. (1987). Multicopy expression vectors carrying the lac repressor gene for regulated high-level expression of genes in *Escherichia coli*. *Gene*. 51, 255-267.
- 20 Stewart, V. & Yanofsky, C. (1985). Evidence for transcription antitermination control of tryptophanase operon expression in *Escherichia coli* K-12. *Journal of Bacteriology*, 164, 731-740.
- 25 Suter-Crazzolara, C. & Unsicker, K. (1995). Improved expression of toxic proteins in *E. coli*. *BioTechniques*, 19, 202-204.
- 30 Yanofsky, C. et al. (1981). The complete nucleotide sequence of tryptophan operon of *E. coli*. *Nucleic Acids Research*, 9, 24, 6647-6668.
- Yansura, D.G. & Bass, S.H. (1997). Application of the *E. coli* trp promoter. *Methods in Molecular Biology*, 62, 55-62.
- 35 Yansura, D.G. & Henner, D.J. (1990). Use of *Escherichia coli* trp promoter for direct expression of proteins. In Anonymous, *Methods of Enzymology*. (pp. 54-60). San Diego, CA: Academic Press, Inc.

ART 34 AMDT

CLAIMS

1. Method for producing a recombinant protein of interest whose gene is placed under the control of the Ptrp tryptophan operon promoter, characterized in that it comprises the following steps:

- a) transforming a prokaryotic cell with a vector containing a nucleic acid sequence which is capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell, and integrating said sequence into the DNA of said host cell; and beforehand, subsequently or simultaneously, introducing into said prokaryotic cell all, or part, of the sequence of a promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter or its transcription product;
- b) transforming said prokaryotic cell with a vector containing a gene encoding said recombinant protein of interest;
- c) culturing said transformed cell in a culture medium which allows the expression of the recombinant protein; and
- d) recovering the recombinant protein from the culture medium or from said transformed cell.

2. Method for producing a recombinant protein of interest according to Claim 1, in which the nucleic acid sequence which is capable of inactivating the gene encoding a TnaA tryptophanase is introduced into the DNA of the prokaryotic host cell according to the chromosomal integration method described in Example 1 or 2.

3. Method for producing a recombinant protein of interest according to either of Claims 1 and 2, in which said nucleic acid sequence introduced into said



host cell is introduced without any other DNA element which would allow a selective advantage to be associated therewith.

4. Method for producing a recombinant protein of interest according to one of Claims 1 to 3, in which said nucleic acid introduced into said host cell is introduced at the tryptophanase operon locus.

5. Method for producing a recombinant protein of interest according to one of Claims 1 to 4, characterized in that said method also comprises, between step a) and b), a resolution and a screening step.

6. Method for producing a recombinant protein of interest according to one of Claims 1 to 5, in which the induction of said promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter or its transcription product is obtained by any means enabling an inhibitory or activating effect to be exerted on said promoter.

7. Production method according to Claim 6, in which the induction of said promoter which is followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter or its transcription product is obtained either:

- a) by choosing a suitable carbon source in the culture medium; or
- b) by adding tryptophan to the culture medium; or
- c) by a combination of a) and b).

8. Method according to one of Claims 1 to 7, characterized in that the prokaryotic host cell is a Gram-negative bacterium.

9. Method according to one of Claims 1 to 8, characterized in that the prokaryotic host cell is *E. coli*.

10. First construct for transforming a prokaryotic host cell which can be transformed with a second construct for expressing a gene encoding a recombinant protein of interest placed under the control of the P<sub>trp</sub> tryptophan operon promoter in a prokaryotic host cell, characterized in that the first construct comprises a nucleic acid sequence which is capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell.

11. First construct according to Claim 10, characterized in that it also comprises, upstream of said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell, all or part of the nucleic acid sequence of the P<sub>tna</sub> tryptophanase operon promoter.

12. First construct according to either of Claims 10 and 11, characterized in that said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell comprises a mutated fragment of the coding sequence of said TnaA tryptophanase.

13. First construct according to Claim 12, characterized in that said mutated fragment is obtained by inserting a stop codon at a position such that the sequence of the mutated fragment thus obtained encodes a protein fragment lacking tryptophanase activity.

14. First construct according to either of Claims 12 and 13, characterized in that said mutated fragment is a mutated fragment of the coding sequence of the TnaA tryptophanase of said host cell.

15. First construct according to Claim 10, characterized in that said nucleic acid sequence capable of inactivating the gene encoding a TnaA tryptophanase when said nucleic acid sequence is introduced into said host cell is the nucleic acid

sequence comprising all or part of the sequence of a promoter followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter or its transcription product.

16. First construct according to Claim 15, characterized in that said promoter followed, in the 3' position, by a nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter, is all, or a part permitting promoter activity, of the Ptna tryptophanase operon promoter.

17. First construct according to Claim 16, characterized in that said nucleic acid sequence encoding a molecule which is ribonucleotide or protein in nature, and which acts negatively on the Ptrp promoter, is the sequence encoding the TrpR tryptophan operon aporepressor or one of its biologically active fragments.

18. Vector containing a first construct according to one of Claims 10 to 17.

19. Vector according to Claim 18, characterized in that it is the vector pMAK705 [tnaAt] as defined in Example 1 or the vector pMAK705 [Ptna :trpR :3'tna].

20. Prokaryotic host cell transformed with a vector according to either of Claims 18 and 19.

21. Prokaryotic host cell according to Claim 20, characterized in that it is *E. coli*.




FIGURE 1




FIGURE 2

2/4




FIGURE 3

3/4




FIGURE 4A




FIGURE 4B




FIGURE 5





FIGURE 6



Please type a plus sign (+) inside this box

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number PF 83 PCT Seq ju

First Named Inventor L. Chevalet

## COMPLETE IF KNOWN

Application Number 09 /673,288

Filing Date October 13, 2000

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL CONSTRUCTS FOR CONTROLLED EXPRESSION OF RECOMBINANT PROTEINS IN PROKARYOTIC CELLS

the specification of which

(Title of the Invention)

☐ is attached hereto  
OR

☒ was filed on (MM/DD/YYYY) April 14, 1999 as United States Application Number: PCT International

Application Number FR99/00874 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Claimed	Certified Copy Attached?	
				YES	NO
FR98/04638	FRANCE	04/14/98	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Please type a plus sign (+) inside this box → ☒

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/FR99/00874	April 14, 1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☐ Registered practitioner(s) name/registration number listed below


Place Customer  
Number Bar Code  
Label here

Name	Registration Number	Name	Registration Number
GORDON W. HUESCHEN	16,157		
G. PATRICK SAGE	37,710		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.


Direct all correspondence to: ☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below


Name	The Firm of Gordon W. Hueschen				
Address	715 The "H" Building				
Address	310 East Michigan Avenue				
City	Kalamazoo	State	MI	ZIP	49007
Country	US	Telephone	616-382-0030	Fax	616-382-2030

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**Name of Sole or First Inventor:** ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname			
Laurent		CHEVALET			
Inventor's Signature			Date	24/10/2000	
Residence: City	State	Country	FRANCE FRX	Citizenship	FR
Post Office Address	2 rue des Acacias				
Post Office Address	ANNEMASSE				
City	State	ZIP	74100	Country	FRANCE

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto



Please type a plus sign (+) inside this box → ☒

PTO/SB/02A (3-97)  
Approved for use through 9/30/98. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

### ADDITIONAL INVENTOR(S)

#### Supplemental Sheet

Page \_\_\_ of \_\_\_

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Alain

ROBERT

Inventor's  
Signature

Date

24/10  
2000

Residence: City

State

Country

FRX  
FRANCE

Citizenship

FR

Post Office Address

12 rue de Romagny

Post Office Address

City

ANNEMASSE

State

ZIP

74100

Country

FRANCE

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Jean-Yves

BONNEFOY

Inventor's  
Signature

Date

24/10  
2000

Residence: City

State

Country

FRX  
FRANCE

Citizenship

FR

Post Office Address

Les Noyers

Post Office Address

City

LE SAPPEY

State

ZIP

74250

Country

FRANCE

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Thien Ngoc

NGUYEN

Inventor's  
Signature

Date

24/10  
2000

Residence: City

State

Country

FRX  
FRANCE

Citizenship

FR

Post Office Address

7 Les Petits Hutins, Lathoy

Post Office Address

SAINT JULIEN EN GENEVOIS

City

State

ZIP

74160

Country

FRANCE

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.